Resources

CAR T-Cell Therapy Perceptions

Subsequent to a report of a chromosomal abnormality in CAR T-cells in a patient treated in an allogeneic CAR T-cell therapy clinical trial, the FDA has placed a hold on allogeneic CAR T-cell therapy clinical trials being conducted by that company.

InCrowd wanted to understand how this FDA action affected oncologists’ and hematologists’ perceptions of CAR T-cell therapy in both the allogeneic and autologous spaces and gene therapy in general.

Download the latest InCrowd Instant Insights report to learn how 76 US oncologists, hematologists, and hematology-oncologists felt about the future of CAR T-Cell therapy and the impact of FDA actions on their perceptions of gene therapy. 

Please fill out the form below to access this content

Name(Required)
Consent
This field is for validation purposes and should be left unchanged.

Related Resources

Why Diversity Matters to Patients

Why Diversity Matters to Patients

How does a diverse patient audience feel about representation among their own physicians? Is the diversity outlook improving among healthcare professionals? Find out in our latest report from the 2023 Pharma Market Research Conference. We examined: Satisfaction with...

read more
ASH 2022 Real-Time Round-Up

ASH 2022 Real-Time Round-Up

The 2022 Annual Meeting of the American Society of Hematology (ASH) took place in person from December 10th to the 13th. InCrowd wanted to learn from those Hematologists and Hematology-Oncologists who attended these two objectives: Explore which condition had the most...

read more